[Histonet] Re: [IHCRG] ER clone 1D5 or SP1 ?

[Hadi Yaziji]

Patsy and all of the wonderful technical colleagues,

The ER guidelines are already in print, and you can download the  
article from the CAP website. Yes, you are correct about the upper  
fixation limit for ER, which was adopted from our consensus conference  
that included a number of experienced scientists (Yaziji H, et al.  
Applied Immunohistochemistry Dec 2008).

Regarding HER2 guidelines, DO NOT CHANGE YOUR TECHNICAL STAFF SCHEDULE  
YET. The panel is meeting now to deliberate on increasing the upper  
limit of fixation for HER2 to 72 hours. We are pushing hard on this,  
but 1/2 of the panel is made of medical oncologists who do not know  
much about tissue fixation.

Once the changes are made, I promise to share the news with the groups  
first thing if they don't get it through CAP publication.

Hadi

================================
Hadi Yaziji, M.D., Medical Director
Vitro Molecular Laboratories
President,
Ancillary Pathways
7000 62nd Avenue, PH-C
Miami, FL 33143
T 305-740-4440
F. 786-513-0175
www.vitromolecular.com
www.ancillarypath.com


On Apr 26, 2010, at 12:46 PM, Patsy Ruegg wrote:

> Did I understand correctly from Dr. Hammond in Florida that the ER  
> ASCO/CAP guidelines extended the fixation time to 72 hours?  Are  
> they changing the Her2 guidelines to match the ER?  If so, has that  
> happened yet?  I have people very anxious to stop having techs work  
> on the weekends to comply with the 48 hour fixation limits.
>
> Thank you,
>
> Patsy
>
> Patsy Ruegg, HT(ASCP)QIHC
> IHCtech, LLC
> Fitzsimmons BioScience Park
> 12635 Montview Blvd. Suite 215
> Aurora, CO 80010
> P-720-859-4060
> F-720-859-4110
> wk email pruegg <@t> ihctech.net
> web site www.ihctech.net
>
>
> This email is confidential and intended solely for the use of the  
> Person(s) ('the intended recipient') to whom it was addressed. Any  
> views or opinions presented are solely those of the author. It may  
> contain information that is privileged & confidential within the  
> meaning of applicable law. Accordingly any dissemination,  
> distribution, copying, or other use of this message, or any of its  
> contents, by any person other than the intended recipient may  
> constitute a breach of civil or criminal law and is strictly  
> prohibited. If you are NOT the intended recipient please contact the  
> sender and dispose of this e-mail as soon as possible.
> From: ihcrg <@t> googlegroups.com [mailto:ihcrg <@t> googlegroups.com] On  
> Behalf Of Van Eyck, Deb
> Sent: Monday, April 26, 2010 10:30 AM
> To: ancillarypath <@t> mac.com; ihcrg Group (E-mail); histonet netserver
> Subject: RE: [IHCRG] ER clone 1D5 or SP1 ?
>
> This is a great discussion lets also talk about PR clones since the  
> ASCO/CAP guidelines just came out ------Hadi or Rich I know they  
> only list two PR clones one is Dako 1294-----what is the other 312?  
> Deb
>
> From: ihcrg <@t> googlegroups.com [mailto:ihcrg <@t> googlegroups.com] On  
> Behalf Of ancillarypath <@t> mac.com
> Sent: Sunday, April 25, 2010 7:36 PM
> To: ihcrg Group (E-mail); histonet netserver
> Subject: Re: [IHCRG] ER clone 1D5 or SP1 ?
>
> When we started our lab 3 years ago, we began with SP1 from day 1,  
> so I don't have any experience with either 1D5 or 6F11 except in my  
> previous labs. 1D5 is an excellent clone, and seems to be more  
> specific than SP1 in the work-up of metastatic carcinoma of unknown  
> primary site, based on the published literature. The advantage of  
> 6F11 is that, for those of us who use the Allred scoring system,  
> it's the only clone that was clinically validated by Harvey et al.  
> (JCO 1999) for this purpose. I agree with Rich.
>
> For those who use SP1, it's a very good clone as a predictive marker  
> in breast cancer. But again, in the setting of metastatic workup, it  
> is NOT recommended, as it will pick up too many primary lung cancers  
> and some colon cancers (personal experience).
>
> Hadi
>
> ================================
> Hadi Yaziji, M.D., Medical Director
> Vitro Molecular Laboratories
> President,
> Ancillary Pathways
> 7000 62nd Avenue, PH-C
> Miami, FL 33143
> T 305-740-4440
> F. 786-513-0175
> www.vitromolecular.com
> www.ancillarypath.com
>
>
>
> On Apr 25, 2010, at 3:04 PM, Richard Cartun wrote:
>
>
> I have looked at several clones over the years and I prefer clone  
> 6F11.
>
> Richard
>
> Richard W. Cartun, Ph.D.
> Director, Histology & Immunopathology
> Director, Biospecimen Collection Programs
> Assistant Director, Anatomic Pathology
> Hartford Hospital
> 80 Seymour Street
> Hartford, CT  06102
> (860) 545-1596 Office
> (860) 545-2204 Fax
>
>
>
>>> "Taylor, Jean" <jtaylor <@t> meriter.com> 4/23/2010 11:17 AM >>>
>
> I'm wondering which clone of ER most labs are using?
>
> Thanks,
> Jean Taylor, HT(ASCP)QIHC
> IHC Tech
> Meriter Health Services
> Madison, WI
>
>
> -- 
> Subscription settings: http://groups.google.com/group/ihcrg/subscribe?hl=en
>
>
>
> This information is confidential and intended solely for the use of  
> the individual or entity to whom it is addressed. If you have  
> received this email in error please notify the sender or our  
> Customer Support Center at (262) 928-2777. We have scanned this e- 
> mail and its attachments for malicious content. However, the  
> recipient should check this email and any attachments for the  
> presence of viruses. ProHealth Care accepts no liability for any  
> damage caused by any virus transmitted by this email.